Lead-212 PSV359 Therapy for Patients With Solid Tumors

This study tests a new type of targeted radiation therapy called Lead-212 PSV359 — a radioactive drug designed to find and attack solid tumors — in patients whose cancer has progressed despite standard treatments. **You may be eligible if...** - You are 18 or older with a confirmed solid tumor (locally advanced or metastatic) - Your cancer has continued growing despite standard therapy, or no standard therapy exists - A special scan (SPECT/CT with a companion imaging agent) shows your tumor takes up the drug - You are in good general health with a life expectancy of more than 3 months **You may NOT be eligible if...** - You have cancer that has spread to the brain - You are pregnant or breastfeeding - You have another active cancer - You have an active, uncontrolled infection - You are allergic to the study drug or its ingredients Talk to your doctor to see if this trial is right for you.